Trials / Completed
CompletedNCT03305809
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 344 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3154207 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2017-11-09
- Primary completion
- 2020-07-10
- Completion
- 2020-07-10
- First posted
- 2017-10-10
- Last updated
- 2021-07-23
- Results posted
- 2021-07-23
Locations
77 sites across 3 countries: United States, Canada, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03305809. Inclusion in this directory is not an endorsement.